{"id":"aripiprazole-or-other-oral-antipsychotics","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Akathisia"},{"rate":"15-20%","effect":"Headache"},{"rate":"10-15%","effect":"Anxiety"},{"rate":"10-15%","effect":"Insomnia"},{"rate":"8-12%","effect":"Nausea"},{"rate":"5-10%","effect":"Weight gain"},{"rate":"5-10%","effect":"Tremor"},{"rate":"5-10%","effect":"Sedation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aripiprazole acts as a partial agonist at dopamine D2 receptors in the brain, which distinguishes it from typical antipsychotics that are full antagonists. This partial agonism allows it to reduce dopamine signaling when it is excessive (in psychosis) while maintaining baseline dopaminergic tone. Additionally, it has agonist activity at serotonin 5-HT1A receptors, contributing to its efficacy in treating both positive and negative symptoms of schizophrenia and other psychiatric conditions.","oneSentence":"Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors that modulates dopaminergic and serotonergic neurotransmission to treat psychotic and mood disorders.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:40.922Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (acute manic or mixed episodes)"},{"name":"Major depressive disorder (adjunctive treatment)"},{"name":"Autism spectrum disorder (irritability)"},{"name":"Tourette's disorder"}]},"trialDetails":[{"nctId":"NCT06433635","phase":"PHASE4","title":"Sequential Multiple Assignment Randomized Trial for Bipolar Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-10-01","conditions":"Bipolar I Disorder, Depression","enrollment":2726},{"nctId":"NCT06049953","phase":"","title":"Maternal And Infant Antipsychotic Study","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2023-09-29","conditions":"Antipsychotics, Pregnancy","enrollment":200},{"nctId":"NCT05554627","phase":"PHASE4","title":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","status":"WITHDRAWN","sponsor":"VA Office of Research and Development","startDate":"2023-10-27","conditions":"Depressive Disorder, Major","enrollment":""},{"nctId":"NCT03643159","phase":"PHASE4","title":"A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-06-28","conditions":"Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder","enrollment":2},{"nctId":"NCT00177164","phase":"PHASE3","title":"Risperdal Consta for Bipolar Disorder","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2003-11","conditions":"Bipolar I Disorder","enrollment":50},{"nctId":"NCT00508157","phase":"PHASE4","title":"A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2007-11","conditions":"Metabolic Syndrome, Schizophrenia","enrollment":125},{"nctId":"NCT01207414","phase":"PHASE4","title":"Switching to Iloperidone From Other Antipsychotics in Schizophrenia","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-08","conditions":"Schizophrenia","enrollment":501}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6138,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Aripiprazole or other oral antipsychotics","genericName":"Aripiprazole or other oral antipsychotics","companyName":"Otsuka Pharmaceutical Development & Commercialization, Inc.","companyId":"otsuka-pharmaceutical-development-commercialization-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors that modulates dopaminergic and serotonergic neurotransmission to treat psychotic and mood disorders. Used for Schizophrenia, Bipolar I disorder (acute manic or mixed episodes), Major depressive disorder (adjunctive treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}